The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis.

Lozano-Ortega, G., Walker, D., Rogula, B., Deighton, A., Johnston, K., Hawkins, N. and Dmochowski, R. (2019) The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis. Urology, 127, pp. 1-6. (doi: 10.1016/j.urology.2019.02.005) (PMID:30790650)

[img]
Preview
Text
181507.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

580kB

Abstract

This study compared the efficacy and safety of mirabegron and onabotulinumtoxinA in the management of treatment-experienced patients with overactive bladder. The network meta-analysis was based on evidence from a systematic literature review of randomized controlled trials and a post-hoc analysis of treatment-experienced subpopulations from mirabegron studies. Nineteen trials described in 21 publications were included. Overall, compared to mirabegron, there was some evidence that onabotulinumtoxinA was associated with improved outcomes, including reductions in the number of micturitions in a 24-hour period, and the number of incontinence episodes. However, mirabegron was associated with a lower risk of urinary tract infections compared with onabotulinumtoxinA.

Item Type:Articles
Additional Information:The present study was initiated by Astellas Pharma Global Development, Inc., and funding for the conduct of this study was provided by Astellas Pharma Global Development, Inc.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Hawkins, Professor Neil
Authors: Lozano-Ortega, G., Walker, D., Rogula, B., Deighton, A., Johnston, K., Hawkins, N., and Dmochowski, R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Urology
Publisher:Elsevier
ISSN:0090-4295
ISSN (Online):0090-4295
Published Online:18 February 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Urology 127:1-6
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record